ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD Lagerbericht

Marktkapitalisierung: US$2.6b

ACADIA Pharmaceuticals Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Steve Davis

Geschäftsführender

US$7.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts11.3%
Amtszeit als Geschäftsführer9yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements2.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder8.9yrs

Jüngste Management Updates

Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

Recent updates

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 26

The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Apr 24
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue

Mar 12

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing

Feb 29

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

Jan 23

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jan 03
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Dec 04
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

May 22
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah

Oct 19

FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide

Sep 12

Acadia: Powerful Unfolding Catalysts

Aug 03

Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome

Jul 18

FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet

Jun 29

Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth

May 07
Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Steve Davis im Vergleich zu den Einnahmen von ACADIA Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

US$31m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$8mUS$857k

-US$61m

Sep 30 2023n/an/a

-US$149m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$14mUS$822k

-US$216m

Sep 30 2022n/an/a

-US$217m

Jun 30 2022n/an/a

-US$205m

Mar 31 2022n/an/a

-US$214m

Dec 31 2021US$10mUS$793k

-US$168m

Sep 30 2021n/an/a

-US$192m

Jun 30 2021n/an/a

-US$262m

Mar 31 2021n/an/a

-US$260m

Dec 31 2020US$8mUS$768k

-US$282m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$225m

Mar 31 2020n/an/a

-US$238m

Dec 31 2019US$8mUS$744k

-US$235m

Sep 30 2019n/an/a

-US$248m

Jun 30 2019n/an/a

-US$268m

Mar 31 2019n/an/a

-US$276m

Dec 31 2018US$7mUS$720k

-US$245m

Sep 30 2018n/an/a

-US$249m

Jun 30 2018n/an/a

-US$252m

Mar 31 2018n/an/a

-US$256m

Dec 31 2017US$15mUS$700k

-US$289m

Vergütung im Vergleich zum Markt: SteveDie Gesamtvergütung ($USD7.59M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD6.80M).

Entschädigung vs. Einkommen: SteveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Steve Davis (63 yo)

9yrs

Amtszeit

US$7,587,014

Vergütung

Mr. Stephen R. Davis, also known as Steve, J. D. served as the Director at Heron Therapeutics Inc. since September 2019 until February 21, 2023. He has been the Chief Executive Officer of ACADIA Pharmaceut...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Stephen Davis
President9yrsUS$7.59m0.11%
$ 2.9m
Mark Schneyer
Executive VP & CFO3yrsUS$2.59m0.026%
$ 677.1k
Brendan Teehan
Executive VP2.8yrsUS$2.62m0.031%
$ 807.8k
James Kihara
VP, Chief Accounting Officer & Corporate Controller4.1yrskeine Daten0.0087%
$ 222.4k
Elizabeth Thompson
Executive VP and Head of Research & Developmentless than a yearkeine Datenkeine Daten
Benir Ruano
Senior Vice President of Technical Development & Operations1.8yrskeine Datenkeine Daten
Albert Kildani
Senior Vice President of Investor Relations & Corporate Communicationsless than a yearkeine Datenkeine Daten
Jennifer Rhodes
Executive VPless than a yearkeine Datenkeine Daten
Holly Valdiviez
Senior VP & Head of Sales2.7yrskeine Datenkeine Daten
Rob Ackles
Senior VP & Chief People Officer2.7yrskeine Datenkeine Daten
Bob Mischler
Senior Vice President of New Product Planning & Strategyno datakeine Datenkeine Daten
Ponni Subbiah
SVP, Global Head of Medical Affairs & Chief Medical Officer4.8yrskeine Datenkeine Daten

2.7yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: ACADDas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Stephen Davis
President9yrsUS$7.59m0.11%
$ 2.9m
Laura Brege
Independent Director16.3yrsUS$392.75k0.012%
$ 312.0k
Julian Baker
Independent Director8.8yrsUS$377.75k0.062%
$ 1.6m
Paul Anderson
Member of the Scientific and Clinical Advisory Boardno datakeine Datenkeine Daten
Edmund Harrigan
Independent Director8.8yrsUS$387.75k0.015%
$ 397.2k
Daniel Soland
Independent Director9.5yrsUS$387.75k0.021%
$ 536.4k
Arvid Carlsson
Member of the Scientific and Clinical Advisory Boardno datakeine Datenkeine Daten
Carol Tamminga
Member of the Scientific and Clinical Advisory Boardno datakeine Datenkeine Daten
Herbert Meltzer
Member of the Scientific and Clinical Advisory Boardno datakeine Datenkeine Daten
James Daly
Independent Director8.7yrsUS$387.75k0.015%
$ 381.6k
Stephen Biggar
Independent Chairman of the Board11.7yrsUS$432.75k0.062%
$ 1.6m
Elizabeth Garofalo
Independent Director4yrsUS$377.75k0.014%
$ 348.4k

8.9yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: ACADDie Vorstandsmitglieder gelten als erfahren (8.7 Jahre durchschnittliche Amtszeit).